Hikma Pharmaceuticals and Glenmark Specialty S.A., a subsidiary of Glenmark Pharma launches Ryaltris in the US. It is a combination of olopatadine hydrochloride and mometasone furoate and formulated as a nasal spray. Ryaltris is approved by the US Food and Drug Administration (FDA) for the treatment of symptoms of seasonal allergic rhinitis (SAR) in adult and pediatric patients 12 years of age and older.
- Read more about Hikma launches allergic rhinitis nasal spray in the US
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/hikma-launches-allergic-rhinitis-nasal-spray-in-the-us
No comments:
Post a Comment